Visceral leishmaniasis: Experimental models for drug discovery
Author Information
Author(s): Suman Gupta, Nishi
Primary Institution: Central Drug Research Institute (CSIR), Lucknow, India
Conclusion
The review discusses various experimental models for drug discovery against visceral leishmaniasis, highlighting the limitations and advantages of each model.
Supporting Evidence
- Visceral leishmaniasis is a serious disease with significant morbidity and mortality.
- Current drug treatments have serious side effects and limitations.
- Experimental models are essential for developing new therapeutics against leishmaniasis.
Takeaway
Scientists are trying to find better ways to test new medicines for a disease called leishmaniasis, which is caused by tiny germs. They use different animal models to see how well these medicines work.
Methodology
The review evaluates in vitro and in vivo systems for drug screening against Leishmania, focusing on the promastigote and amastigote stages of the parasite.
Limitations
No single animal model accurately reproduces human leishmaniasis, and existing methods are often labor-intensive and time-consuming.
Want to read the original?
Access the complete publication on the publisher's website